echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > 【Probe 24H】Customized penis transplantation in the UK! The world's first new drug to delay the process of type 1 diabetes has been approved!

    【Probe 24H】Customized penis transplantation in the UK! The world's first new drug to delay the process of type 1 diabetes has been approved!

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Introduction: Customized penis transplantation is implemented in the UK; The world's first new drug to delay the onset of type 1 diabetes was approved; Rongcan Biotech completed tens of millions of yuan pre-A round financing.
    .
    .
    .
    .
    .
    BioDiscovery pays attention to "medicine" with you and explores the value of biotechnology!

    01

    Custom penis transplantation is implemented in the UK

    Recently, University College London (ULC) achieved a custom-sized penis transplant.

    The patient who received the transplant was 47-year-old Malcom MacDonald
    .
    In 2014, Malcom underwent testicular and penile resection with irreversible testicular decay due to sepsis, which caused his fingers
    , toes and penis to darken.

    To ease Malcom's pain, the National Society for Organisational Technology funded £50,000 to grow and transplant a new penis
    from Malcom's arm.
    After communicating with David Ralph, a penis construction expert at University College London, Malcom requested that the new penis be customized to be 15cm in size, which is 5cm
    longer than before.
    Doctors removed a flap from his left arm, rolled it up to form a temporary penis, and created a urethra
    inside.
    Due to intraoperative hypoxemia, the new penis must be connected to the blood vessels in the arm to keep the tissue healthy
    .
    After the penis has grown in the arm for some time, the doctor successfully transplants it into the patient's groin
    .
    According to doctors, the transplanted new penis allowed Malcom to regain sexual function and urinary capacity
    .

    02

    The world's first delay

    New drug for type 1 diabetes attack approved

    On November 18, the US FDA announced that it had approved Provention Bio's drug Tzield (teplizumab) for the purpose of delaying the disease progression
    in specific high-risk groups of type 1 diabetes.
    The US FDA press release pointed out that this is also the first drug
    that can delay the onset of type 1 diabetes.

    Type 1 diabetes is a chronic disease
    .
    Due to damage to the patient's pancreatic β cells, the amount of insulin they secrete in their bodies is very small, even almost zero! Insulin is an important hormone in the body, and insufficient secretion can lead to abnormal increases in blood sugar levels and abnormal glucose metabolism, inducing a series of metabolic problems
    .

    teplizumab is an anti-CD3 monoclonal antibody that promises to stop attacking insulin-producing cells by binding to specific immune cells
    .
    Previous studies showed that the proportion of patients at high risk of type 1 diabetes who received teplizumab reached 50% at a median follow-up of 2.
    5 years, more than twice as much as the placebo group (22%) (HR=0.
    457, P=0.
    01).

    In addition, studies have shown that teplizumab treatment significantly improves the function of pancreatic islet β cells, as well as the ability to
    secrete insulin.

    03

    Rongcan Biotech completed tens of millions of yuan

    RMB Pre-A round of financing

    Recently, Rongcan Biotechnology, an independent innovation platform enterprise of nucleic acid technology, announced the completion of tens of millions of yuan in pre-A round of financing, which was led by well-known medical and health professional funds
    .
    This round of financing will help Rongcan Biotech accelerate product development and team building, and promote the leading pipeline into clinical research
    .

    Rongcan Biotech was founded in June 2020 by senior returnee doctors and a team of domestic experts, the founding team has decades of experience in the nucleic acid industry, has successfully designed and developed LNP carriers with completely independent intellectual property rights, and co-signed with Professor Robert Langer, obtained a new cationic lipid carrier patent authorization in the United States (the founder of Rongcan is the first inventor), and is also one of the few teams in China to jointly develop cationic lipid carriers with Professor Robert Langer and obtain US patent authorization

    04

    Freeline sells subsidiary

    Stop hemophilia B gene therapy

    Recently, Freeline Therapeutics (Freeline) made three major moves to cut expenses and find gene therapy partners: sell subsidiaries, stop investment in hemophilia B gene therapy, and lay off employees, so as to retain enough funds to maintain operations until 2024
    .

    Founded in 2015 and based in Stevenage, UK, Freeline Therapeutics is a pioneer in gene therapy for rare diseases
    .
    Its therapy is based on a next-generation proprietary AAV vector platform, and its leading plan is gene therapy
    for hemophilia B.

    05

    Southern Yuan Medicine

    Tens of millions in pre-A round financing

    Recently, Nanjing Nanfang Yuan Biotechnology Co.
    , Ltd.
    (hereinafter referred to as Southern Yuan), an innovative platform for the development and production of functional polysaccharides, received tens of millions of yuan in pre-A round financing, led by Suzhou Yanying Investment Management Co.
    , Ltd.
    and followed by Changzhou Zhengkaifeng Venture Capital Partnership
    .

    The amount of financing in this round is planned to be used for raw material preparation, quality system construction and product preclinical research
    .
    Southern Yuan was established in January 2022 and received angel round financing
    of about RMB 10 million during the same period.
    Its founder team has more than 30 years of academic research, drug development and industrialization experience in the field of functional polysaccharides and metabolic drugs, and has published more than 100 Class I scientific papers
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.